Outcome of Combination Chemotherapy with Docetaxel, Estramustine Phosphate, and Carboplatin after Docetaxel and Prednisolone Therapy in Patients with Metastatic Castration-Resistant Prostate CancerReport as inadecuate




Outcome of Combination Chemotherapy with Docetaxel, Estramustine Phosphate, and Carboplatin after Docetaxel and Prednisolone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer - Download this document for free, or read online. Document in PDF available to download.

We retrospectivelyreviewed the outcome of docetaxel, EMP, and carboplatin DEC as second-linechemotherapy in castration-resistant prostate cancer CRPC patients previouslytreated with docetaxel-prednisolone DP. Nineteen patients pretreated with DP receiveda DEC regimen which consisted of a 28-day cycle of docetaxel 60 mg-m2 intravenously IV on day 1, carboplatin IV to an area under the curve of 5on day 1, and EMP 560 mg orally daily. The DEC therapy was continuedintermittently after two consecutive courses. End points were DEC effect on prostate-specificantigen PSA, radiographic response, progression-free survival PFS, andoverall survival OS. All patients received DP before DEC administration witha median of 6 cycles range, 1 - 12. Mean follow-up duration was 19.0 monthsafter starting DEC therapy; median total number of the therapy cycles was 2range, 1 - 11. Thirteen patients 68.4% showed a PSA decrease; 6 31.6%showed a decrease in the PSA level of ≥50%, including 4 with no PSA response toDP. Grade 3-4 neutropenia and febrile neutropenia were observed in 13 68.4%and 2 10.5% patients, respectively. The median PFS following DEC was 3.7months. The median OS was 18.0 months. In univariate analyses, patients with≤12 months from CRPC to DEC had shorter PFS and OS, whereas PSA response to DPwas not associated with PFS or OS in CRPC patients treated with DEC after DP. Inconclusion, DEC retains some clinical benefits for CRPC patients pretreatedwith DP, even in patients without any response to DP. Therefore, they may be aneffective and feasible treatment option for CRPC patients after first-linedocetaxel therapy, particularly for those deemed unfit for novel endocrine andchemotherapeutic drugs.

KEYWORDS

Chemotherapy, Carboplatin, Docetaxel, Estramustine Phosphate, Prostate Cancer

Cite this paper

Ito, R. , Narita, S. , Tsuruta, H. , Numakura, K. , Maeno, A. , Saito, M. , Inoue, T. , Tsuchiya, N. , Satoh, S. and Habuchi, T. 2016 Outcome of Combination Chemotherapy with Docetaxel, Estramustine Phosphate, and Carboplatin after Docetaxel and Prednisolone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Cancer Therapy, 7, 471-479. doi: 10.4236-jct.2016.77049.





Author: Ryuichi Ito, Shintaro Narita*, Hiroshi Tsuruta, Kazuyuki Numakura, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Norihiko Tsuchi

Source: http://www.scirp.org/



DOWNLOAD PDF




Related documents